Extension of Phase II Studies ABE4869g and ABE4955g in Patients with Mild to Moderate Alzheimer Disease
Location(s): United States
This Phase II, open-label extension (OLE), multicenter study will evaluate the long-term safety and tolerability of crenezumab in patients with mild to moderate Alzheimer's disease who have participated in and completed the treatment period of the Phase II Study ABE4869g or ABE4955g. Patients will receive crenezumab at the same dosing frequency, dose level and route of administration they were assigned to after the Week 73 visit of Study ABE4869g or ABE4955g. Patients who received placebo in Study ABE4869g or ABE4955g will receive active drug. Anticipated time on study treatment is 94 weeks.